Rat Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein (Active)
611€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Rat Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein (Active)
category
Proteins and Peptides
provider
Abbexa
reference
abx692180
tested applications
SDS-PAGE
Description
Rat PCSK9 Protein is a recombinant protein from Rat produced in HEK293 Cells. A DNA sequence encoding the rat PCSK9 (NP_954862.2) (Met 1-Gln 691) was expressed, fused with a polyhistidine tag at the C-terminus.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | PCSK9 |
| Host | HEK293 cells |
| Origin | Rat |
| Observed MW | Molecular Weight: 72.8 kDa Sequence Fragment: Met1-Gln691 Tag: C-terminal His tag Validity: The validity for this protein is 12 months. |
| Expression | Recombinant |
| Purity | > 97% (SDS-PAGE) |
| Size 1 | 20 µg |
| Form | |
| Tested Applications | SDS-PAGE |
| Buffer | Lyophilized from sterile PBS, pH 7.4. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at -20°C or -80°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | NP_954862.2 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Protein PCSK9 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Related Products
Guinea pig PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit
Ver Producto
Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA Kit
Ver Producto